In the following video, health care editor/analyst David Williamson discusses the FDA advisory committee vote that sent shares of Arena Pharmaceuticals soaring over 70% in a single day. Obesity drug lorcaserin received an 18-4 recommendation supporting approval. What does this vote mean for Arena's competitors, and is the company poised for monster returns? For a closer look, watch the video and Fool On.

Arena is on the cutting edge for obesity treatment, yet it isn't one of the many dynamic recommendations made to Motley Fool Rule Breakers subscribers over the years. Now's a great time to discover the next rule-breaking multibagger that the newsletter has unearthed. It's a free report. Want it? Get it.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.